MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Search

Quidel Corp

Open

34.33 2.94

Overview

Share price change

24h

Current

Min

32.92

Max

34.18

Key metrics

By Trading Economics

Employees

6,600

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-20.42% downside

Dividends

By Dow Jones

Next Earnings

11 Feb 2026

Market Stats

By TradingEconomics

Market Cap

305M

1.9B

Previous open

31.39

Previous close

34.33

Quidel Corp Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jan 2026, 19:05 UTC

Major Market Movers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 Jan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 Jan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Jan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 Jan 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 Jan 2026, 23:10 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 Jan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 Jan 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 Jan 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 Jan 2026, 21:08 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 Jan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 Jan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 Jan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 Jan 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 Jan 2026, 19:03 UTC

Earnings

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 Jan 2026, 18:50 UTC

Earnings

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 Jan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 Jan 2026, 17:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

13 Jan 2026, 17:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 Jan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 Jan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 Jan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Comparison

Price change

Quidel Corp Forecast

Price Target

By TipRanks

-20.42% downside

12 Months Forecast

Average 26.5 USD  -20.42%

High 31 USD

Low 22 USD

Based on 5 Wall Street analysts offering 12 month price targets forQuidel Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

3

Hold

1

Sell

Financials

$

About Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat